CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for INIFY Laboratories AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

INIFY Laboratories AB
Scheeles vag 3
Phone: +46 8267330p:+46 8267330 SOLNA, 171 65  Sweden Ticker: INIFYINIFY
Business Summary
INIFY Laboratories AB is a Sweden-based medical research company that provides cancer diagnostics through laboratory services within pathology. The Company uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The Company origins from ContextVision.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-------

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Lars O.Sanden 61 1/1/2021 1/1/2021
Chief Executive Officer FredrikPalm 1/1/2022 1/1/2022
Chief Financial Officer Ann-CharlotteLinderoth 1/1/2022 1/1/2022
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 45,236,750 (As of 12/31/2023)
Stock Exchange: OSL


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024